Literature DB >> 6248189

Hemorrhage from carcinoma of the lung.

R R Miller, D H McGregor.   

Abstract

During a retrospective analysis of 877 cases of lung cancer, we explored the relationships between cell type, site, cavitation, varying degrees of hemoptysis, and radiation therapy. Massive terminal hemoptysis (29 cases) was found to be significantly associated with cavitated (P less than 0.0001 squamous cell carcinoma (P = 0.0002), ARISING IN EITHER THE RIGHT OR LEFT MAIN BRONCHI (P less than 0.0001). Lesser, nonlethal degrees of hemoptysis (140 cases) were not cell-type associated, occurring in approximately 15% of cases of all major tumor types. Radiotherapy, although employed more frequently in the massive-hemoptysis population, did not appear to be causally related to hemoptysis of any degree. An interesting case, which provoked the above study, is described: a patient with bronchogenic squamous cell carcinoma and terminal hemoptysis due to a tumor fistula between the primary lesion and the left atrial chamber. The forms of cardiac involvement in lung cancer are discussed.

Entities:  

Mesh:

Year:  1980        PMID: 6248189     DOI: 10.1002/1097-0142(19800701)46:1<200::aid-cncr2820460133>3.0.co;2-v

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

1.  Do tumor cavitation and sex in resected stage I non-small-cell lung cancer correlate with prognosis?

Authors:  Meng Wang; Jing Zhao; Yi Pan; Yan-Jun Su; Jian You; Xiao-Liang Zhao; Chang-Li Wang
Journal:  World J Surg       Date:  2009-03       Impact factor: 3.352

Review 2.  Cavitary pulmonary disease.

Authors:  L Beth Gadkowski; Jason E Stout
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

3.  High dose rate endobronchial brachytherapy for the treatment of lung cancer: current status and indications.

Authors:  P Barber; R Stout
Journal:  Thorax       Date:  1996-04       Impact factor: 9.139

Review 4.  A systematic approach to the management of massive hemoptysis.

Authors:  Christopher Radchenko; Abdul Hamid Alraiyes; Samira Shojaee
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 5.  Treatment of unresectable lung cancer with brachytherapy.

Authors:  C Aygun; J E Blum
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

6.  Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.

Authors:  Alan B Sandler; Joan H Schiller; Robert Gray; Isaiah Dimery; Julie Brahmer; Meghna Samant; Lisa I Wang; David H Johnson
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

7.  Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab.

Authors:  Matthew D Hellmann; Jamie E Chaft; Valerie Rusch; Michelle S Ginsberg; David J Finley; Mark G Kris; Katharine A R Price; Christopher G Azzoli; Matthew G Fury; Gregory J Riely; Lee M Krug; Robert J Downey; Manjit S Bains; Camelia S Sima; Nabil Rizk; William D Travis; Naiyer A Rizvi; Paul K Paik
Journal:  Cancer Chemother Pharmacol       Date:  2013-06-28       Impact factor: 3.333

Review 8.  Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts.

Authors:  M Reck; F Barlesi; L Crinò; C I Henschke; D Isla; S Stiebeler; D R Spigel
Journal:  Ann Oncol       Date:  2011-11-04       Impact factor: 32.976

9.  Endobronchial stent insertion to manage hemoptysis caused by lung cancer.

Authors:  In Hee Chung; Mi-hyun Park; Doh Hyung Kim; Gyeong Sik Jeon
Journal:  J Korean Med Sci       Date:  2010-07-21       Impact factor: 2.153

10.  Fatal hemothorax caused by pseudomesotheliomatous carcinoma of the lung.

Authors:  Petur Snaebjornsson; Cornelis G Vos; Koen J Hartemink; Rutger J Lely; Setareh M Samii; Katrien Grünberg; Marinus A Paul
Journal:  Patholog Res Int       Date:  2011-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.